Myriad diversifies companion Dx portfolio with RBM purchase
This article was originally published in Clinica
Executive Summary
Myriad Genetics is moving beyond oncology and into new disease areas with the planned acquisition of privately-held biomarker screening service provider Rules-Based Medicine (RBM).